Teclistamab,Daratumumab,Pomalidomide,Lenalidomide,Bortezomib,Nirogacestat
Genmab,Janssen,springworks therapeutics,Takeda,bms
['mmsm', 'multiple myeloma', ' dara ', 'imab ']
teclistimab + dara + len shows high rates of vgpr/cr in relapsed/refractory multiple myeloma. 90% infection rate with almost 40% grade 3 or higher make it hard to justify moving to upfront given high rates of deep responses seen with quads in this setting imo #ash22 #mmsm
Director of Hematologic Oncology @HolyNameMedCtr. Proud product of @ColumbiaCancer @TulaneMedicine @DukeMedicine @Cornell. Views are my own.